Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

Howard L. Kaufman, Lisa H. Butterfield, Pierre G. Coulie, Sandra Demaria, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Ira Mellman, Pamela S. Ohashi, Willem W. Overwijk, Suzanne L. Topalian, Francesco M. Marincola

Research output: Contribution to journalArticle

Abstract

The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule were initially developed in 1981 following a revision of the Declaration of Helsinki in 1975. Most academic facilities follow the Common Rule in the regulation of clinical trials research. Recently, the government has suggested a revision of the Common Rule to include more contemporary and streamlined oversight of clinical research. In this commentary, the leadership of the Society for Immunotherapy of Cancer (SITC) provides their opinion on this plan. While the Society recognizes the considerable contribution of clinical research in supporting progress in tumor immunotherapy and supports the need for revisions to the Common Rule, there is also some concern over certain elements which may restrict access to biospecimens and clinical data at a time when high throughput technologies, computational biology and assay standardization is allowing major advances in understanding cancer biology and providing potential predictive biomarkers of immunotherapy response. The Society values its professional commitment to patients for improving clinical outcomes with tumor immunotherapy and supports continued discussion with all stakeholders before implementing changes to the Common Rule in order to ensure maximal patient protections while promoting continued clinical research at this historic time in cancer research.

Original languageEnglish (US)
Article number37
JournalJournal for ImmunoTherapy of Cancer
Volume4
Issue number1
DOIs
StatePublished - Jun 21 2016

Fingerprint

Immunotherapy
Research
Neoplasms
Helsinki Declaration
Behavioral Research
Computational Biology
Biomedical Research
Biomarkers
Clinical Trials
Technology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Kaufman, H. L., Butterfield, L. H., Coulie, P. G., Demaria, S., Ferris, R. L., Galon, J., ... Marincola, F. M. (2016). Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. Journal for ImmunoTherapy of Cancer, 4(1), [37]. https://doi.org/10.1186/s40425-016-0142-0

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. / Kaufman, Howard L.; Butterfield, Lisa H.; Coulie, Pierre G.; Demaria, Sandra; Ferris, Robert L.; Galon, Jérôme; Khleif, Samir N.; Mellman, Ira; Ohashi, Pamela S.; Overwijk, Willem W.; Topalian, Suzanne L.; Marincola, Francesco M.

In: Journal for ImmunoTherapy of Cancer, Vol. 4, No. 1, 37, 21.06.2016.

Research output: Contribution to journalArticle

Kaufman, HL, Butterfield, LH, Coulie, PG, Demaria, S, Ferris, RL, Galon, J, Khleif, SN, Mellman, I, Ohashi, PS, Overwijk, WW, Topalian, SL & Marincola, FM 2016, 'Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule', Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 37. https://doi.org/10.1186/s40425-016-0142-0
Kaufman, Howard L. ; Butterfield, Lisa H. ; Coulie, Pierre G. ; Demaria, Sandra ; Ferris, Robert L. ; Galon, Jérôme ; Khleif, Samir N. ; Mellman, Ira ; Ohashi, Pamela S. ; Overwijk, Willem W. ; Topalian, Suzanne L. ; Marincola, Francesco M. / Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. In: Journal for ImmunoTherapy of Cancer. 2016 ; Vol. 4, No. 1.
@article{85e20e3204b74e41a0c81a964422575d,
title = "Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule",
abstract = "The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule were initially developed in 1981 following a revision of the Declaration of Helsinki in 1975. Most academic facilities follow the Common Rule in the regulation of clinical trials research. Recently, the government has suggested a revision of the Common Rule to include more contemporary and streamlined oversight of clinical research. In this commentary, the leadership of the Society for Immunotherapy of Cancer (SITC) provides their opinion on this plan. While the Society recognizes the considerable contribution of clinical research in supporting progress in tumor immunotherapy and supports the need for revisions to the Common Rule, there is also some concern over certain elements which may restrict access to biospecimens and clinical data at a time when high throughput technologies, computational biology and assay standardization is allowing major advances in understanding cancer biology and providing potential predictive biomarkers of immunotherapy response. The Society values its professional commitment to patients for improving clinical outcomes with tumor immunotherapy and supports continued discussion with all stakeholders before implementing changes to the Common Rule in order to ensure maximal patient protections while promoting continued clinical research at this historic time in cancer research.",
author = "Kaufman, {Howard L.} and Butterfield, {Lisa H.} and Coulie, {Pierre G.} and Sandra Demaria and Ferris, {Robert L.} and J{\'e}r{\^o}me Galon and Khleif, {Samir N.} and Ira Mellman and Ohashi, {Pamela S.} and Overwijk, {Willem W.} and Topalian, {Suzanne L.} and Marincola, {Francesco M.}",
year = "2016",
month = "6",
day = "21",
doi = "10.1186/s40425-016-0142-0",
language = "English (US)",
volume = "4",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

AU - Kaufman, Howard L.

AU - Butterfield, Lisa H.

AU - Coulie, Pierre G.

AU - Demaria, Sandra

AU - Ferris, Robert L.

AU - Galon, Jérôme

AU - Khleif, Samir N.

AU - Mellman, Ira

AU - Ohashi, Pamela S.

AU - Overwijk, Willem W.

AU - Topalian, Suzanne L.

AU - Marincola, Francesco M.

PY - 2016/6/21

Y1 - 2016/6/21

N2 - The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule were initially developed in 1981 following a revision of the Declaration of Helsinki in 1975. Most academic facilities follow the Common Rule in the regulation of clinical trials research. Recently, the government has suggested a revision of the Common Rule to include more contemporary and streamlined oversight of clinical research. In this commentary, the leadership of the Society for Immunotherapy of Cancer (SITC) provides their opinion on this plan. While the Society recognizes the considerable contribution of clinical research in supporting progress in tumor immunotherapy and supports the need for revisions to the Common Rule, there is also some concern over certain elements which may restrict access to biospecimens and clinical data at a time when high throughput technologies, computational biology and assay standardization is allowing major advances in understanding cancer biology and providing potential predictive biomarkers of immunotherapy response. The Society values its professional commitment to patients for improving clinical outcomes with tumor immunotherapy and supports continued discussion with all stakeholders before implementing changes to the Common Rule in order to ensure maximal patient protections while promoting continued clinical research at this historic time in cancer research.

AB - The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule were initially developed in 1981 following a revision of the Declaration of Helsinki in 1975. Most academic facilities follow the Common Rule in the regulation of clinical trials research. Recently, the government has suggested a revision of the Common Rule to include more contemporary and streamlined oversight of clinical research. In this commentary, the leadership of the Society for Immunotherapy of Cancer (SITC) provides their opinion on this plan. While the Society recognizes the considerable contribution of clinical research in supporting progress in tumor immunotherapy and supports the need for revisions to the Common Rule, there is also some concern over certain elements which may restrict access to biospecimens and clinical data at a time when high throughput technologies, computational biology and assay standardization is allowing major advances in understanding cancer biology and providing potential predictive biomarkers of immunotherapy response. The Society values its professional commitment to patients for improving clinical outcomes with tumor immunotherapy and supports continued discussion with all stakeholders before implementing changes to the Common Rule in order to ensure maximal patient protections while promoting continued clinical research at this historic time in cancer research.

UR - http://www.scopus.com/inward/record.url?scp=84997764847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997764847&partnerID=8YFLogxK

U2 - 10.1186/s40425-016-0142-0

DO - 10.1186/s40425-016-0142-0

M3 - Article

VL - 4

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 37

ER -